1-2 of 2
Brigitte Corront
Close
Sort by
Journal Articles

Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival

Pierre Feugier, MD, PhD, Remi Letestu, MD, Sylvie Chevret, Thérèse Aurran, MD, Beatrice Mahe, Bruno Cazin, MD, Olivier Tournilhac, MD, PhD, Hervé Maisonneuve, Olivier Casasnovas, MD, Alain Delmer, MD, Véronique Leblond, MD, PhD, Bruno Royer, MD, Brigitte Corront, MD, Roselyne Delepine, Sandrine Vaudaux, Eric Van Den Neste, MD, PhD, Marie C Béné, PharmSciD, PhD, Florence Cymbalista, MD, PhD, Stéphane Leprêtre, MD
Journal: Blood
Blood (2013) 122 (21): 2870.
https://doi.org/10.1182/blood.V122.21.2870.2870
Published: 2013
Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS) : CLL2007FMP (for fit medically patients).

Stephane Lepretre, Therese Aurran, Beatrice Mahe, Bruno Cazin, Olivier Tournihlac, Hervé Maisonneuve, Olivier Casasnovas, Alain Delmer, Veronique Leblond, Bruno Royer, Brigitte Corront, Sylvie Chevret, Roselyne Delepine, Sandrine Vaudaux, Eric Van Den Neste, marie-Christine Béné, Florence Cymbalista, Pierre Feugier
Journal: Blood
Blood (2009) 114 (22): 538.
https://doi.org/10.1182/blood.V114.22.538.538
Published: 2009